Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 2115-2117

  Jeng, Michael R ^a   Fuh, Beng ^b   Blatt, Julie ^c   Gupta, Anita ^d   Merrow, Arnold C ^d   Hammill, Adrienne ^d   Adams, Denise ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiosarcoma; Bevacizumab; KRAS L19F; Malignant transformation

Indexed keywords

BEVACIZUMAB; DOCETAXEL; GEMCITABINE; PROPRANOLOL; RAPAMYCIN; SORAFENIB; STEROID; THYROID HORMONE; TRAMETINIB; VINCRISTINE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CAPILLARY HEMANGIOMA; CASE REPORT; CAUCASIAN; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN TISSUE; INFANT; LIVER HEMANGIOMA; LIVER INJURY; LUNG LESION; LUNG NODULE; LYMPHEDEMA; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HEMANGIOMA; SKIN HEMANGIOMA; TREATMENT RESPONSE; TUMOR BIOPSY; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; HEMANGIOMA; HEMANGIOSARCOMA; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL TRANSFORMATION, NEOPLASTIC; HEMANGIOMA; HEMANGIOSARCOMA; HUMANS; INFANT; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922599340     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25067     Document Type: Article

References (20)

1. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649-2651.
2. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Peds 2010; 157:340-342.
3. Awan S, Davenport M, Portmann B, et al. Angiosarcoma of the liver in children. J Pediatr Surg 1996; 31:1729-1732.
4. Cioffi A, Reichert S, Antonsecu CR, et al. Angiosarcomas and other sarcomas of endothelial origin. Hematol Oncol Clin N Am 2013; 27:975-988.
5. Elliott P, Kleinschmidt I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup Environ Med 1997; 54:14-18.
6. Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep 2013; 15:347-355.
7. Ferrari A, Casanova M, Bisogno G, et al. Malignant vascular tumors in children and adolescents: A report from the Italian and German Soft Tissue Sarcoma Cooperative Group. Med Pediatr Oncol 2002; 39:109-114.
8. Deyrup A, Miettinen M, North PE, et al. Pediatric cuteneous angioarcomas: A clinicopathologic study of 10 cases. Am J Surg Pathol 2009; 35:70-75.
9. Miller T, Friended IJ. Hemangiomas: New insights and classification. Pediatr Ann 2005; 34:179-187.
10. Ono S, Tanioka M, Fujisawa A, et al. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Arch Dermatol 2012; 148:683-685.
11. Donghi D, Dummer R, Cozzio A. Complete remission in a patient with multi-focal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. Br J Dermatol 2010; 162:697-699.
12. Naguib A, Wilson CH, Adams D, et al. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signaling 2011; 6:2.
13. Weihrauch M, Bader M, Lehnert G, et al. Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients with occupationally exposed to vinyl chloride. Environ Mol Mutagen 2002; 40:36-40.
14. Przygodzki RM, Finkelstein SD, Keohavong P, et al. Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. Lab Invest 1997; 76:153-159.
15. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010; 22:351-355.
16. Jeltsch M, Leppanen V-M, Saharinen P, et al. Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harbor Perspect Biol 2013; 5:1-22.
17. Wang AX, Qi WY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life 2013; 65:748-758.
18. Rosen A, Thimon S, Ternant D, et al. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol 2010; 163:225-227.
19. Fuller CK, Charlson JA, Dankle SK, et al. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 2010; 63:e83-e84.
20. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013; 24:257-263.